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ESTIMATING LIFETIME ECONOMIC BURDEN OF STROKE IN KOREA 
ACCORDING TO THE AGE OF ONSET: USING NATIONAL HEALTH 
INSURANCE CLAIMS DATABASE
Kang HY1, Lim SJ1, Chang HS1, Liew D2
1Yonsei University, Seoul, South Korea, 2The University of Melbourne, Melbourne, Victoria, 
Australia
OBJECTIVES: Little is known about variations in resource use and cost of stroke 
among patients experiencing stroke at different age. Recent observation of getting 
younger among stroke patients in Korea raises a concern on the loss of labor forces. 
Thus, this study was conducted to compare per-person lifetime cost of stroke accord-
ing to the age of stroke onset from the Korea societal perspective. METHODS: 
The cost for fatal stroke was measured as one-time cost. The cost for non-fatal stroke 
was estimated as a lifetime cost using Markov cohort simulation. Then, weighted 
average cost was calculated based on the proportion of fatal or non-fatal stroke among 
Korean population. Transition probabilities were derived from published sources. 
Average cost for fatal stroke and 1st- and 2nd-year of non-fatal stroke was estimated 
from the National Health Insurance claims records. RESULTS: The lifetime economic 
impact of stroke is 10.6^ 4.5 times higher for men aged 45 or 55 (196.6^83.7 million 
Korean won) than those 65 (8.2 million KW). Women experiencing stroke at 45 or 
55 (69.5 or 38.1 million KW) showed 3.2^1.8 times higher lifetime cost than women 
at 65 (21.1 million KW). While stroke from those aged 45^64 accounted for only 
20% of incidence, the total national lifetime costs of stroke was explained by 72% 
from this age group. CONCLUSIONS: Higher lifetime burden and increasing inci-
dence of stroke among younger population in Korea suggests that more effective 
strategy targeting young population should be adopted to prevent stroke incidence in 
the nation.
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COST–ANALYSIS OF STROKE PATIENTS WITH THE INTEGRATED 
WESTERN AND ORIENTAL MEDICAL TREATMENT IN SOUTH KOREA
Ku MJ1, Lee EK2
1SookMyung Women’s University, seoul, seoul, South Korea, 2Sook Myung Women’s 
University, Seoul, South Korea
OBJECTIVES: In Korea, not only has the number of stroke patients increased, but 
also the integrated western and oriental medical treatment became popular. In this 
study, treatment costs for stroke were compared for those with integrated treatment 
with the costs of western treatment. METHODS: During the period between May 
2006 and February 2009, the treatment cost was analyzed for 318 stroke patients 
who were admitted to the emergency room of a secondary hospital. Medical records 
were collected and detailed cost items were compared. SAS Version 9.1 was used for 
data analysis. RESULTS: The estimated annual treatment cost for a stroke patient is 
KRW 10.55 million for the integrated treatment, whereas it is KRW 8.11 for western 
treatment only. The biggest parts of integrated treatment cost were for rehabilitation 
and oriental medical treatments. Because much of oriental treatments is not covered 
by health insurance, patients’ burden were heavier compared to western treatment. 
Oriental treatment comprises 16.3% for the inpatients, whereas higher at 65.2% for 
outpatients. In addition, although the incidence of ischemic stroke was higher than 
that of hemorrhagic stroke, the average days of hospitalization and average total 
treatment cost per patient were higher in the case of hemorrhagic stroke in Korea. 
CONCLUSIONS: The integrated medical treatment costs more than only the western 
treatment. However, more detailed study with more integrated treatment patients will 
be needed to generalize the study results.
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INCREMENTAL COSTS OF HYPERTENSION, HYPERGLYCEMIA, 
HYPERLIPIDEMIA, AND THEIR COMBINATIONS
Tang CH1, You SL2, Sun CA3, Bai CH4, Pwu RF5, Hung ST1
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OBJECTIVES: Hypertension, hyperglycemia and hyperlipidemia (HHH) are impor-
tant health problems due to their relationship with cardiovascular, cerebrovascular 
and peripheral vascular diseases. Previous studies have found that individuals with 
HHH were associated with more health care resource use, yet no study has been con-
ducted in Taiwan to estimate the cost impact of HHH on society. This study aimed 
to determine the incremental costs among the individuals with HHH, compared with 
no symptom individuals in Taiwan with no symptons. METHODS: A retrospective 
case-control analysis was performed using a unique dataset that linked the 2002 
 Taiwanese Survey on Prevalence of Hypertension, Hyperglycemia and Hyperlipidemia 
(TwSHHH) with the 2003–2006 National Health Insurance (NHI) claims records. 
Study cases were 1277 individuals with hypertension, 409 individuals with hypergly-
cemia, and 1808 individuals in Taiwan with hyperlipidemia. For each symptom group, 
controls without symptoms were matched at a 1:3 ratio by demographics. The differ-
ence in medical costs between cases and controls was assumed to be attributable to 
HHH. Negative binomial regression based on generalized estimating equations were 
performed to compute regression-adjusted annual total medical costs. All costs were 
reported in NT dollars (US$1.00  NT$34.42 in 2003). RESULTS: Adjusted mean 
annual number of outpatient visits for HHH were 5.81, 11.62 and 4.36, respectively. 
Mean annual number of hospital days for HHH were 1.67, 3.13 and 0.97, respec-
tively. Mean annual drug costs for HHH were NT$8,612, NT$ 14,665, and NT$ 
3,578, respectively. Mean annual total medical costs for HHH were NT$21,117, NT$ 
34,853, and NT$ 9,678, respectively. CONCLUSIONS: This study demonstrated a 
substantial increase in resource usage in terms of the frequency of care use and medical 
costs associated with HHH. Indirect morbidity costs need to be estimated in the future 
to provide the information on the overall economic burden of HHH to policy-makers 
in Taiwan.
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OBJECTIVES: Orthopaedic surgery is one of the highest risk factors for venous 
thromboembolism.The main objective of this retrospective database analysis was to          
determine direct medical costs for pulmonary embolism (PE) in patient undergoing 
orthopaedic surgery in Slovakia from the payer perspective. METHODS: A retrospec-
tive database analysis of biggest health insurance company in Slovakia was conducted. 
Resources used and their respective costs in connection with PE were collected for 
patients undergoing elective total hip replacement (THR) or elective total knee repla-
cement (TKR) during the period from January 1, 2007 till January 1, 2008. All 
resources and costs were categorized in four groups: inpatient, outpatient, drugs and 
examinations. Costs in Euro were calculated with ofﬁcial exchange rate 30,126 Sk/a. 
Cost comparison between groups of patients with PE and without PE after orthopaedic 
surgery was done. RESULTS: The group of 3069 patients (1121 men and 1948 
women) after elective orthopaedic surgery was analyzed. There were 2153 patients 
with THR and 916 with TKR. The average age was 64.5 and 68.4 years in THR and 
in TKR group respectively. Eighteen cases of PE were identiﬁed in the whole group 
(11 in THR and 7 in TKR). Average direct medical costs for group of patients were 
a5964 with PE and a3170 without PE. There was a following structure of costs (WITH         
and WITHOUT pulmonary embolism): 1) inpatient: a5064 and a2516; 2) outpatient: 
a171 and a141; 3) drugs: a339 and a251; and 4) examinations: a390 and a262. 
CONCLUSIONS: Average direct medical costs for patients with PE after elective ort-
hopedic surgery are a5964. This is almost 90% more then the average direct medical 
costs for patients without PE. Main driver of increased costs is inpatient stay at 
intensive care unit and at internal medicine department after episode of pulmonary 
embolism.
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DIRECT COSTS OF DIAGNOSTIC AND TREATMENT OF PATIENTS 
WITH ATRIAL FIBRILLATION IN GERMANY
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OBJECTIVES: Atrial Fibrillation (AF) is an important public health problem. The aim 
of the study is to assess the costs of AF in the German health care system. METHODS: 
From a payer’s perspective we determined annual direct medical costs of patients with 
paroxysmal, persistent and permanent AF based on 2008 prices. Cost calculation is 
based on a bottom-up approach. Resource items (e.g. laboratory tests) and quantity 
of resource use were identiﬁed by literature research and by consulting medical 
experts. Prices for outpatient treatment and drugs were obtained from ofﬁcial cata-
logues considering prices. Inpatient treatment was priced by use of the German Diag-
nosis Related Groups System. Costs were calculated in a cost database by relating 
resource use and corresponding price. Appropriate discounts and rebates were taken 
into consideration. RESULTS: The annual average aggregated costs of paroxysmal AF 
are a1394, of persistent AF are a2130 and of permanent AF are a1073 without the 
costs for diagnostic investigations. Including these costs there are a1644 for paroxys-
mal AF and a2441 for persistent AF. Permanent AF is not considered, because patients 
are not diagnosed as permanent by the ﬁrst doctor’s contact. From payer’s perspective, 
the main cost driver was hospitalization (a756 to 1809), especially due to the proce-
dures of electrical cardioversion. CONCLUSIONS: The cost evaluation shows that 
AF is related with high costs for the social health insurance in Germany. Because the 
data used are predominantly taken from publications, it might not reﬂect the real 
resource use for Germany. In the same way data raised by experts opinion do not 
reﬂect a generally applicable resource use. Despite these limitations the present study 
shows valid data of costs for AF in Germany. Our results are comparable with the 
results of another German cost-of-illness-analyses and the results of the German 
Competence Network on AF.
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HEALTH CARE COSTS AND RESOURCE UTILIZATION FOR ACUTE 
CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT 
DIABETES MELLITUS
Zhao Z1, Zhu B2, Anderson J1, Bayt T2, LeNarz L2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Diabetes is an independent prognostic factor for increased risk for 
ischemic heart disease. This study evaluates differences in health care costs and 
resource utilization for acute coronary syndrome (ACS) patients with and without 
diabetes mellitus (DM). METHODS: A retrospective cohort study was conducted 
using a large US administrative claims database. Patients aged 18–65 years hospital-
ized with a primary diagnosis of ACS between January 1, 2005 and December 31, 
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2006 were identiﬁed and categorized into two groups: with DM and without DM. 
Patients with complete insurance coverage and medication information 1-year prior 
and post the index hospitalization were included. Annual health care costs (in 2008 
US dollars) and resource utilization were compared for both groups (All p  .001 
unless otherwise stated). RESULTS: Of 12,502 patients who met the study selection 
criteria, 3,040 (24%) were diabetic and 9,462 (76%) were non-diabetic. Higher 
percent of diabetic patients had at least one all-cause rehospitalization event (49.0% 
vs 35.2%) or cardiovascular-related rehospitalization event (45.5% vs. 32.3%). Mean 
length of stay (LOS) was longer for diabetic patients during the index hospitalization 
(4.3 days vs. 3.3 days), as well as during the rehospitalization event (all-cause: 4.6 
days vs 3.3 days; cardiovascular-related: 4.6 days vs 3.2 days). In addition, patients 
with DM had more physician’s ofﬁce visits (16.3 vs. 12.4), ER visits (0.8 vs. 0.5), and 
outpatient hospital visits (9.0 vs. 7.1) during the 12-month follow-up period. Both 
cohorts had similar index ACS hospitalization costs ($32,026 vs. $29,082) but diabetic 
patients incurred higher rehospitalization costs (all-cause: $19,913 vs $10,947; car-
diovascular-related: $18,256 vs $10,093), outpatient costs ($14,836 vs. $8,617) and 
pharmacy costs ($6,105 vs. $3,921). One-year follow-up health care costs were sig-
niﬁcantly higher for patients with DM compared with those without DM ($40,853 
vs. $23,485). CONCLUSIONS: The presence of DM signiﬁcantly increases health care 
costs and resource utilization for ACS patient.
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ONE-YEAR HEALTH CARE COSTS FOR ACUTE CORONARY SYNDROME 
PATIENTS WITH DIFFERENT TREATMENT STRATEGIES DURING THE 
INITIAL HOSPITALIZATION
Zhao Z, Winget M
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: This study calculated 1-year total health care costs for ACS patients 
and evaluated differences based on treatment strategy for patients during their initial 
hospitalization. METHODS: Commercially insured individuals, aged 18–64, partici-
pating in a large claims database were identiﬁed by a hospitalization with an ACS 
diagnosis between January 2004 and December 2005 with a 1-year follow-up period. 
Patients who had an ACS diagnosis in the prior 12-month to their initial ACS hospi-
talization were excluded. Patients were divided into 3 groups by treatment strategy 
during the initial hospitalization: MM, PCI or CABG. Multivariate linear regression 
was performed to assess the adjusted cost differences across these 3 groups. RESULTS: 
A total of 19,617 ACS patients were identiﬁed, of which 52% (n  10,152) were 
managed by medical therapy, 40% (n  7962) by PCI and 8% (n  1539) by CABG. 
Mean length of stay and per-patient expenditures during the initial hospitalization for 
the MM, PCI and CABG groups were 1.9 days/$10,878, 3.3 days/$31,900 and 9.3 
days/$68,333, respectively. One-year follow-up costs were $25,131 for MM, $21,039 
for PCI, and $22,677 for CABG, where 46%, 42% and 46% of these costs were due 
to rehospitalization, and 4.7%, 10% and 5.9% were due to ACS-related prescription 
drug costs. Controlling for differences in demographics and clinical characteristics, 
CABG patients had approximately $52,365 greater 1-year total health care costs 
compared to MM patients (p  0.01) while PCI patients had approximately $15,952 
higher total health care costs than MM patients (p  0.01). Factors associated with 
increased costs included gender, age, comorbidities, initial hospitalization diagnosis, 
treatment strategy and prior health care costs. CONCLUSIONS: Total 1-year health 
care costs are substantial for working-aged patients newly diagnosed with ACS and 
signiﬁcantly different across the three treatment groups. Signiﬁcantly higher costs were 
observed in patients managed interventionally, particularly by CABG, with the major-
ity of these costs incurred during the initial hospitalization.
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BURDEN OF ILLNESS STUDY IN PATIENTS WITH RESISTANT 
HYPERTENSION IN UK
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OBJECTIVES: Resistant hypertension is deﬁned as blood pressure (BP) that remains 
above goal in spite of the concurrent use of three antihypertensive agents from differ-
ent classes. Some patients with resistant hypertension do not receive further treatment, 
potentially increasing the overall burden of disease on the health care system through 
increased health care use. To examine the burden of resistant hypertension to the UK 
health care system and explore the potential cost resulting from non-treatment of 
resistant hypertension. METHODS: The Health Improvement Network computerized 
data from 6.8 million patients in 382 practices was used to randomly select 9,000 
patients with probable or conﬁrmed resistant hypertension. Patients were character-
ized by number of therapies received according to NICE treatment guidelines (three 
therapies: step 3 vs. four or more, step 4). Blood pressure was used to classify patients 
as controlled or uncontrolled hypertension. Associations between covariates and 
patient status were examined using analysis of variance and logistic regressions. 
Pattern of care was assessed for patients in each category using descriptive statistics. 
RESULTS: Mean age of patients with hypertension included in the study was 68.8 
(SD  11.5). Among patients in step 3 at baseline, 57.2% had uncontrolled BP (mean 
BP 151/81 v. 127/73); among patients in step 4, 57.9% were uncontrolled (mean BP 
153/80 v. 136/72). After two years of follow-up, approximately 25% of patients did 
not receive treatment recommended by NICE guidelines. Older male patients with 
diabetes or kidney disease were more likely to have resistant hypertension or uncon-
trolled BP at either step 3 or 4. CONCLUSIONS: A large proportion of patients with 
hypertension do not achieve BP control despite maintaining three or more antihyper-
tensive therapies. The impact of not treating these patients with appropriate therapies 
can substantially contribute to overall burden of hypertension borne by the UK health 
care system.
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LONGITUDINAL COST IMPACT OF ATRIAL FIBRILLATION IN 
PATIENTS SUFFERING FROM CARDIOVASCULAR DISEASES
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OBJECTIVES: To examine the cost impact of atrial ﬁbrillation (AFib) in patients with 
atherothrombotic diseases in a German statutory health insurance population. 
METHODS: Study design: A retrospective review of the medical, hospital and phar-
macy claims data (2004–2005) in the database of a German statutory health insurance. 
We reviewed pharmacy and medical claims data for the years 2004–2005 from an 
insurance covering about 5 Mio insurees. The data of patients suffering from cardio-
vascular diseases (myocardial infarction, stroke or PAD) were available. By using the 
documented ICD-10 codes (I48.10, I48.11, and I48.19) for hospitalizations we identi-
ﬁed patients who experienced Aﬁb during 2004 and 2005. For these patients we 
reviewed all the charges incurred for a one-year period after the initial index event on 
the basis of weekly costs and from the third party payer’s perspective. RESULTS: A 
total of 14,798 patients (mean age: 72 o 10 years) with Aﬁb could be included in the 
analysis. The majority of the patients (55%) were female. The cost for atrial ﬁbrillation 
patients for one year was a7690. The largest portion of the total cost (78%) resulted 
from the costs for hospitalization while the initial hospital stay was associated with 
30% of total costs. Approximately 100% of the study population received prescription 
drugs at an average cost of a1155 per prescription drug user. Compared to the dura-
tion before the initial diagnosis of Aﬁb, the costs increase by the factor 1.4 during the 
ﬁrst year after the event. The majority of costs one year after the event arise during 
the ﬁrst 10 weeks (approx. 50%). CONCLUSIONS: An acute Aﬁb-event in patients 
with atherothrombotic diseases represents a signiﬁcant ﬁnancial burden from the per-
spective of the statutory health insurance population. Improved management of the 
condition is needed to reduce the cost of treatment associated with AF.
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ECONOMIC IMPLICATIONS OF OBESITY AMONG PEOPLE WITH 
ATHEROTHROMBOTIC DISEASE IN AUSTRALIA
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OBJECTIVES: To measure the cost of disease from the governmental perspective 
associated with body weight in people with or at high risk of atherothrombotic disease, 
using a bottom-up approach to cost estimation; and to explore the causes of any dif-
ferences found. METHODS: The health care costs of obesity were estimated from 
2819 participants recruited into the nation-wide Australian REACH Registry with 
established atherothrombotic disease or at least three risk factors for atherothrombo-
sis. Enrolment was in 2004, through primary care general practices. Information was 
collected on the use of cardiovascular drugs, hospitalisations and ambulatory care 
services. ‘Bottom-up’ costing was undertaken by assigning unit costs to each health 
care item, based on Australian Government-reimbursed ﬁgures 2006–2007. Gener-
alised-linear models were used to estimate associations between direct medical costs 
and BMI categories. RESULTS: Annual pharmaceutical costs per-person increased 
with increasing BMI, even after adjusting for gender, age, living place, formal educa-
tion, smoking status, hypertension and diabetes. Adjusted annual pharmaceutical costs 
of overweight and obese patients were higher ($83 (p  0.006) and $142 (0.001), 
respectively) than those of the normal-weight patients. This was due to patients in 
higher BMI categories receiving more pharmaceuticals than normal-weight patients 
with the same condition. There was no signiﬁcant change across the BMI categories 
in annual ambulatory care costs and annual hospital costs. CONCLUSIONS: In these 
patients with, or at high risk of, atherothrombotic disease, annual pharmaceutical 
costs were greater in patients with higher BMI, but there was no such gradient in 
annual hospital or ambulatory care costs. The greater cardiovascular pharmaceutical 
costs for patients of higher BMI remained even after adjusting for a range of demo-
graphic factors and comorbidities, and our results suggest that they are explained by 
a higher number of drugs used for the same condition. Further investigation is needed 
of the reasons for this level of drug utilisation.
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OBJECTIVES: Lost Therapeutic Beneﬁt (LTB) (receiving medication without attaining 
target BP levels) may lead to increased morbidity and mortality due to cardiovascular 
disease. Objectives of this study were to estimate the extent of LTB in patients at high 
risk of atherothrombotic events and to model the impact of attaining target BP levels 
in LTB patients on cardiovascular event rates over a two-year period. METHODS: 
The Australian REACH registry consists of 2872 high-risk patients of which 2856 
(99.4%) were followed for cardiovascular events over a two-year period. The mean 
